AROMATASE INHIBITORS: A NEW HOPE FOR BREAST CANCER PATIENTSAbstract
Breast Cancer is the leading cause of mortality among the women of age 30 to 60. Endocrine therapy used for the treatment has shown promising results in which the anti-estrogen tamoxifen has been the standard first-line treatment used for more than 30 years. But its side effects like resistance, increase risk of thromboembolism, endometrial cancer and uterine sarcoma limits its use. The development of selective Aromatase Inhibitors has offered an alternative approach for postmenopausal patients failing anti-estrogen therapy alone or other hormonal therapies. These drugs are approved as first-line therapy for the treatment of postmenopausal women with metastatic estrogen-dependent breast cancer. They are proven superior to tamoxifen for disease free survival, especially in receptor positive patients and reducing the incidence of colorectal breast cancer.
Anu Mahajan *, Shruti Rawal, PMS Bedi, Nipun Mahajan and Ajay Sharma
Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, India
15 March, 2010
10 April, 2010
21 May, 2010
01 June, 2010